Genetic animal models: focus on schizophrenia

被引:165
作者
Gainetdinov, RR [1 ]
Mohn, AR
Caron, MG
机构
[1] Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Med, Durham, NC 27710 USA
关键词
D O I
10.1016/S0166-2236(00)01886-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The neurobiology of schizophrenia remains poorly understood. Symptoms of schizophrenia are classically thought to be associated with an imbalance of the dopaminergic system. However, the contribution of other neurotransmitters, in particular glutamate, has been increasingly appreciated. The role of individual components of neurotransmitter systems in aberrant behaviors can be experimentally tested in transgenic animals. Dopamine transporter knockout mice display persistently elevated dopaminergic tone and therefore might be appropriate substrates to evaluate the dopamine hypothesis. Similarly, NMDA receptor-deficient mice can be used to evaluate the glutamate hypothesis of schizophrenia. In this review we discuss how such animal models might be relevant for understanding the neurochemical underpinnings of certain manifestations of schizophrenia.
引用
收藏
页码:527 / 533
页数:7
相关论文
共 81 条
  • [1] Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
    Abi-Dargham, A
    Rodenhiser, J
    Printz, D
    Zea-Ponce, Y
    Gil, R
    Kegeles, LS
    Weiss, R
    Cooper, TB
    Mann, JJ
    Van Heertum, RL
    Gorman, JM
    Laruelle, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) : 8104 - 8109
  • [2] A targeted mutation of the D-3 dopamine receptor gene is associated with hyperactivity in mice
    Accili, D
    Fishburn, CS
    Drago, J
    Steiner, H
    Lachowicz, JE
    Park, BH
    Gauda, EB
    Lee, EJ
    Cool, MH
    Sibley, DR
    Gerfen, CR
    Westphal, H
    Fuchs, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (05) : 1945 - 1949
  • [3] PARKINSONIAN-LIKE LOCOMOTOR IMPAIRMENT IN MICE LACKING DOPAMINE D2 RECEPTORS
    BAIK, JH
    PICETTI, R
    SAIARDI, A
    THIRIET, G
    DIERICH, A
    DEPAULIS, A
    LEMEUR, M
    BORRELLI, E
    [J]. NATURE, 1995, 377 (6548) : 424 - 428
  • [4] Barkley R.A., 1990, Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment
  • [5] No evidence for linkage or association between the dopamine transporter gene and schizophrenia in a French population
    BodeauPean, S
    Laurent, C
    Campion, D
    Jay, M
    Thibaut, F
    Dollfus, S
    Petit, M
    Samolyk, D
    dAmato, T
    Martinez, M
    Mallet, J
    [J]. PSYCHIATRY RESEARCH, 1995, 59 (1-2) : 1 - 6
  • [6] Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter
    Bosse, R
    Fumagalli, F
    Jaber, M
    Giros, B
    Gainetdinov, RR
    Wetsel, WC
    Missale, C
    Caron, MG
    [J]. NEURON, 1997, 19 (01) : 127 - 138
  • [7] Haloperidol-induced catalepsy is absent in dopamine D2 but maintained in dopamine D3 receptor knock-out mice
    Boulay, D
    Depoortere, R
    Oblin, A
    Sanger, DJ
    Schoemaker, H
    Perrault, G
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 391 (1-2) : 63 - 73
  • [8] Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine
    Busch, AE
    Karbach, U
    Miska, D
    Gorboulev, V
    Akhoundova, A
    Volk, C
    Arndt, P
    Ulzheimer, JC
    Sonders, MS
    Baumann, C
    Waldegger, S
    Lang, F
    Koepsell, H
    [J]. MOLECULAR PHARMACOLOGY, 1998, 54 (02) : 342 - 352
  • [9] Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence
    Carlsson, A
    Waters, N
    Holm-Waters, S
    Tedroff, J
    Nilsson, M
    Carlsson, ML
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 : 237 - 260
  • [10] Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys
    Castner, SA
    Goldman-Rakic, PS
    [J]. NEUROPSYCHOPHARMACOLOGY, 1999, 20 (01) : 10 - 28